The overall goal of this proposal is to develop a new viral hybrid vector for treatment of genetic liver disease. In order to obtain life- long expression of a therapeutic gene, the vector must transduce hepatocytes efficiently without associated toxic or immunologic side effects and integrate into predictable sites into the host genome. In an attempt to combine the advantages of adenoviral vectors (high titer, infectivity, large capacity) and the integration capability of recombinant AAV, AAV ITRs flanking a reporter gene cassette were incorporated into E1/E3 deleted adenoviral vectors. During replication of these hybrid vectors in 293 cells, a 5.5kb genome (deltaAd.AAV1) was efficiently generated and packaged into adenovirus capsids. The deltaAd.AAV1 genome contained only the AAV-vector cassette linked on both sides to the adenoviral packaging signal and ITRs deltaAd.AAV1 was produced at high titer and purity. This hybrid vector devoid of all viral genes transduced cells in vitro and in vivo with frequencies comparable to rAAV integrating into the host genome randomly. One objective of this proposal is to further characterize the in vivo properties of deltaAd.AAV1. To construct a site-specific integrating deltaAd.AAV vector, the functions of AAV Rep68/78 will be utilized to mediate rescue and integration of a transgene cassette flanked by AAV ITRs into a specific site in human chromosome 19. The central questions of this proposal are: 1) whether the Rep 68/78 functions can be incorporated into deltaAd.AAV without affecting the ability to produce high titer vector. To address this problem, the unique structure of deltaAd.AAV will be applied to bring the rep gene in a transcriptionally active position under the control of a hepatocyte specific promoter only at late stages of virus replication in 293 cells. 2) whether this modified hybrid vector will transfer the Rep68/78 function of site- specific integration transiently to human target cells in vitro and in vivo without toxic side effects. Our hypothesis is that Rep-mediated vector integration occurs via the AAV ITRs without the rep gene, which was placed outside the AAV-ITR-transgene cassette, thus eliminating rep expression upon integration. 3) whether site-specific vector integration can be mediated by Rep protein molecules co-packaged into deltaAd.AAV capsids. Initial transduction experiments will be performed in human and murine cell cultures. For initial in vivo studies, immunodeficient mice with hepatic tumors derived from transformed human cells that can be targeted by systemic vector application will be used.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21DK055590-02
Application #
6177445
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (J1))
Program Officer
Mckeon, Catherine T
Project Start
1999-05-01
Project End
2001-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
2
Fiscal Year
2000
Total Cost
$151,719
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Stecher, Hartmut; Carlson, Cheryl A; Shayakhmetov, Dmitry M et al. (2003) Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats. Methods Mol Med 76:135-52
Li, Zong-Yi; Otto, Kevin; Richard, Robert E et al. (2002) Dimerizer-induced proliferation of genetically modified hepatocytes. Mol Ther 5:420-6
Carlson, Cheryl A; Shayakhmetov, Dmitry M; Lieber, Andre (2002) Restoration of a functional open reading frame by homologous recombination between two adenoviral vectors. Mol Ther 6:99-105
Carlson, Cheryl A; Shayakhmetov, Dmitry M; Lieber, Andre (2002) An adenoviral expression system for AAV rep78 using homologous recombination. Mol Ther 6:91-8
Shayakhmetov, Dmitry M; Carlson, Cheryl A; Stecher, Hartmut et al. (2002) A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells. J Virol 76:1135-43
Stecher, H; Shayakhmetov, D M; Stamatoyannopoulos, G et al. (2001) A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. Mol Ther 4:36-44
Shayakhmetov, D M; Papayannopoulou, T; Stamatoyannopoulos, G et al. (2000) Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 74:2567-83
Steinwaerder, D S; Lieber, A (2000) Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther 7:556-67
Steinwaerder, D S; Carlson, C A; Lieber, A (1999) Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats. J Virol 73:9303-13